KR880007473A - 신규의 비사이클릭디포스포네이트 화합물 - Google Patents
신규의 비사이클릭디포스포네이트 화합물 Download PDFInfo
- Publication number
- KR880007473A KR880007473A KR870014561A KR870014561A KR880007473A KR 880007473 A KR880007473 A KR 880007473A KR 870014561 A KR870014561 A KR 870014561A KR 870014561 A KR870014561 A KR 870014561A KR 880007473 A KR880007473 A KR 880007473A
- Authority
- KR
- South Korea
- Prior art keywords
- diphosphonic acid
- pyridine
- pharmaceutically acceptable
- octahydro
- hydrogen
- Prior art date
Links
- -1 Bicyclic Diphosphonate Compounds Chemical class 0.000 title claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 4
- 150000002148 esters Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Paints Or Removers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (16)
- 하기 일반식을 갖는, 질소-함유, 포화비사이클릭 사이클로펜탄 링-함유 디포스폰산 및 약제학적으로 허용되는 이의 염 에스테르.상기 식에서, m 및 n 및 m+n은 약 0 내지 약 5의 정수이고, p는 0 내지 2의 정수이고, R1은 각각 수소, 탄소수 약 1 내지 약 6의 알킬, OR3, -CO2R3, -O2CR3, -NR2 3, -N(R3)(CO)R3, -C(O)N(R3)2, 할로겐, -C(O)R3, 페닐, 벤질, 니트로 및 그의 결합물로 이루어진 그룹으로부터 독립적으로 선택되고, R2는 수소, 탄소수 약 1 내지 약 6의 알킬, R3C(O)-, 페닐, 및 벤질이며, R3은 각기 수소 및 탄소수 약 1 내지 약 3의 알킬로 이루어진 그룹으로부터의 독립적으로 선택된다.
- 제1항에 있어서, 상기 화합물이 비치환 또는 치환된 옥타하이드로-1-피리딘-5,5-디포스폰산, 비치환 또는 치환된 옥타하이드로-2-피리딘-5,5-디포스폰산, 비치환 또는 치환된 옥타하이드로-1-피리딘-6,6-디포스폰산, 비치환 또는 치환된 옥타하이드로-2-피리딘-6,6-디포스폰산, 비치환 또는 치환된 옥타하이드로-1-피리딘-7,7-디포스폰산, 비치환 또는 치환된 옥타하이드로-2-피리딘-7,7-디포스폰산, 및 약제학적으로 허용되는 이의 염 및 에스테르로 이루어진 그룹으로부터 선택된 옥타하이드로 피리딘 디포스폰산, 염 또는 에스테르 화합물임을 특징으로 하는 질소-함유, 포화비사이클릭사이클로펜탄 링-함유 디포스폰산 및 약제학적으로 허용되는 이의 염 및 에스테르.
- 제2항에 있어서, 일반식(A)를 갖는 비치환 또는 치환된 옥타하이드로-1-피리딘-6,6-디포스폰산, 염 및 에스테르 및 일반식(B)를 갖는 비치환 또는 치환된 옥타하이드로-2-피리딘-6,6-디포스폰산, 염 및 에스테르 로 이루어진 그룹으로부터 선택된 옥타하이드로 피리딘 디포스폰산, 및 약제학적으로 허용되는 이의 염 및 에스테르.
- 제3항에 있어서, R1이 각각 수소, 탄소수 약 1내지 약 6의 알킬, -NR3 2및 하이드록시로 이루어진 그룹으로부러 독립적으로 선택되고, , R2가 수소, 탄소수 약 1 내지 약 6의 알킬 및 R3C(O)-임을 특징으로 하는 옥타하이드로 피리딘 디포스폰산 및 약제학적으로 허용되는 이의 염 및 에스테르.
- 하기 일반식을 갖는 옥타하이드로-1-피리딘-6,6-디포스폰산 및 약제학적으로 허용되는 이의 염 및 에스테르.상기식에서, R1은 각각 수소, 탄소수 약 1내지 약 6의 알킬,-CR3,-COR3,-O2CR3,-NR3 2, -N(R3)C(O)R3,-C(O)N, (R3)2, 할로겐, -C(O)R3, 페닐, 벤질, 니트로, 및 그의 결합물로 이루어진 그룹으로부러 독립적으로 선택되여, R2는 수소, 탄소수 약 1 내지 약 6의 알킬, R3C(O)-, 페닐, 및 벤질이며, R3은 각각 수소 및 탄소수 약 1 내지 약 3의 알킬로 이루어진 그룹으로부터 독립적으로 선택된다.
- 제5항에 있어서, R1이 각각 수소, 탄소수 약 1 내지 약 6의 알킬, -NR3 2, 및 하이드록시로 이루어진 그룹으로부터 독립적으로 선택되고, R2가 수소, 탄소수 약 1 내지 약 6의 알킬, 및 R3C(O)-임을 특징으로 하는 옥타하이드로-1-피리딘-6,6-디포스폰산 및 약제학적으로 허용되는 이의 염 및 에스테르.
- 제6항에 있어서, R1이 각각 수소, 에틸, 에틸, -NH2및 하이드록시로 이루어진 그룹으로부러 독립적으로 선택되고, R2가 수소, 에틸 및 에틸로 이루어진 그룹으로부터 선택된 옥타하이드로-1-피리딘-6,6-디포스폰산 및 약제학적으로 허용되는 이의 염 및 에스테르.
- 제7항에 있어서, R1및 R3이 수소인 옥타하이드로-1-피리딘-6,6-디포스폰산 및 약제학적으로 허용되는 염 및 에스테르.
- 시스-옥타하이드로-1-피리딘-6,6-디포스폰산 화합물 및 약제학적으로 허용되는 이의 염 및 에스테르.
- (a)적정유효량의 제1항의 질소-함유, 포화비사이클릭시클로펜탄 링-함유 디포스폰산, 염 또는 에스테르, 및 (b)약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- (a) 적정유효량의 제3항의 옥타하이드로 피리딘 디포스폰산 염 또는 에스테르, 및 (b) 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- (a) 적정유효량의 제5항의 옥타하이드로-1-피리딘-6,6-디포스폰산, 염 또는 에스테르, 및 (b) 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- (a) 적정유효량의 제6항의 옥타하이드로-1-피리딘-6,6-디포스폰산, 염 또는 에스테르, 및 (b) 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- (a) 적정유효량의 제7항의 옥타하이드로-1-피리딘-6,6-디포스폰산, 염 또는 에스테르, 및 (b) 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- (a) 적정유효량의 제8항의 옥타하이드로-1-피리딘-6,6-디포스폰산, 염 또는 에스테르, 및 (b) 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- (a) 적정유효량의 제9항의 옥타하이드로-1-피리딘-6,6-디포스폰산, 염 또는 에스테르, 및 (b) 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/945069 | 1986-12-19 | ||
US06/945,069 US4868164A (en) | 1986-12-19 | 1986-12-19 | Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880007473A true KR880007473A (ko) | 1988-08-27 |
KR950009196B1 KR950009196B1 (ko) | 1995-08-16 |
Family
ID=25482572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870014561A KR950009196B1 (ko) | 1986-12-19 | 1987-12-19 | 비사이클릭 디포스포네이트 화합물 및 이를 함유하는 약제학적 조성물 |
Country Status (18)
Country | Link |
---|---|
US (3) | US4868164A (ko) |
EP (1) | EP0273514B1 (ko) |
JP (1) | JP2573973B2 (ko) |
KR (1) | KR950009196B1 (ko) |
AT (1) | ATE59046T1 (ko) |
AU (1) | AU615886B2 (ko) |
CA (1) | CA1321793C (ko) |
DE (1) | DE3766695D1 (ko) |
DK (1) | DK171068B1 (ko) |
FI (1) | FI87652C (ko) |
HK (1) | HK79393A (ko) |
IE (1) | IE873456L (ko) |
IL (1) | IL84660A (ko) |
MY (1) | MY102266A (ko) |
NO (2) | NO174625C (ko) |
NZ (1) | NZ222985A (ko) |
PH (1) | PH25583A (ko) |
ZA (1) | ZA879502B (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868164A (en) * | 1986-12-19 | 1989-09-19 | Norwich Eaton Pharmaceuticals, Inc. | Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
IL86951A (en) * | 1987-07-06 | 1996-07-23 | Procter & Gamble Pharma | Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them |
DE3822650A1 (de) * | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
EP0642521A1 (en) * | 1992-05-29 | 1995-03-15 | Procter & Gamble Pharmaceuticals | Thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism |
US5753634A (en) * | 1992-05-29 | 1998-05-19 | The Procter & Gamble Company | Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism |
AU662991B2 (en) * | 1992-05-29 | 1995-09-21 | Procter & Gamble Pharmaceuticals, Inc. | Quaternary nitrogen-containing phosphonates for treating abnormal calcium and phosphate metabolism |
HUT69699A (en) * | 1992-05-29 | 1995-09-28 | Procter & Gamble Pharma | Sulfur-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism |
US5763611A (en) * | 1992-05-29 | 1998-06-09 | The Procter & Gamble Company | Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
US5391743A (en) * | 1992-05-29 | 1995-02-21 | Procter & Gamble Pharmaceuticals, Inc. | Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque |
RU2119794C1 (ru) * | 1992-06-30 | 1998-10-10 | Проктер энд Гэмбл Фармасьютикалз, Инк. | Использование фосфонатов и нестероидных противовоспалительных лекарственных средств для лечения артрита, способ лечения |
CA2199252A1 (en) * | 1994-09-09 | 1996-03-14 | Ann Dunbar Geddes | Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone |
EP0753523A1 (en) | 1995-07-10 | 1997-01-15 | Gador S.A. | Amino-substituted bisphosphonic acids |
US7781418B2 (en) * | 2006-12-14 | 2010-08-24 | Isis Innovation Ltd. | Composition for treating bone disorders |
US11793452B2 (en) | 2019-10-03 | 2023-10-24 | Johnson & Johnson Consumer Inc. | Method of visualizing and quantifying remineralization |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3553314A (en) * | 1968-12-23 | 1971-01-05 | Procter & Gamble | Oral compositions for calculus retardation |
US3979385A (en) * | 1969-11-19 | 1976-09-07 | Henkel & Cie G.M.B.H. | 1-Aminoalkane-1,1-diphosphonic acids and their salts |
DE1958123C3 (de) * | 1969-11-19 | 1978-09-28 | Henkel Kgaa, 4000 Duesseldorf | Verfahren zur Herstellung von 1 -Aminoalkan-1,1 -diphosphonsäuren oder deren Salzen |
US3683080A (en) * | 1970-08-28 | 1972-08-08 | Procter & Gamble | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue |
US3899496A (en) * | 1970-10-06 | 1975-08-12 | Henkel & Cie Gmbh | Production of 1-aminoalkane-1,1-diphosphonic acids |
DE2104476C2 (de) * | 1971-02-01 | 1983-12-01 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur Verhinderung von Ausfällungen in Wasser oder wäßrigen Lösungen |
DE2343196C3 (de) * | 1973-08-27 | 1980-01-10 | Henkel Kgaa, 4000 Duesseldorf | Aiacycloalkan-2^-diphosphonsäuren oder deren wasserlösliche Salze |
US4034086A (en) * | 1973-08-27 | 1977-07-05 | Henkel & Cie G.M.B.H. | Pyrrolidone-5,5-diphosphonic acids |
DE2343147C2 (de) * | 1973-08-27 | 1982-06-09 | Henkel KGaA, 4000 Düsseldorf | Pyrrolidon-5,5-diphosphonsäuren, deren wasserlösliche Salze, und Verfahren zu ihrer Herstellung |
US3988443A (en) * | 1973-08-27 | 1976-10-26 | Henkel & Cie G.M.B.H. | Azacycloalkane-2,2-diphosphonic acids |
DE2456666A1 (de) * | 1974-11-30 | 1976-08-12 | Henkel & Cie Gmbh | Verfahren zum stabilisieren von calcium-hydrogenphosphat-dihydrat gegen hydrolyse |
DE2543349C2 (de) * | 1975-09-29 | 1984-05-10 | Henkel KGaA, 4000 Düsseldorf | Preaparate zur herstellung von99m technetium-radiagnostica |
SE7612534L (sv) * | 1975-12-01 | 1977-06-02 | Henkel & Cie Gmbh | Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning |
DE2745083C2 (de) * | 1977-10-07 | 1985-05-02 | Henkel KGaA, 4000 Düsseldorf | Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung |
US4230700A (en) * | 1977-12-07 | 1980-10-28 | The Procter & Gamble Company | Methods for inhibiting mobilization of calcium phosphate in animal tissue |
SU1002300A1 (ru) * | 1981-10-29 | 1983-03-07 | Ордена Ленина институт элементоорганических соединений им.А.Н.Несмеянова | Способ получени @ -аминозамещенных- @ -оксипропилидендифосфоновых кислот |
DE3428524A1 (de) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4687768A (en) * | 1984-12-21 | 1987-08-18 | The Procter & Gamble Company | Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism |
DE3540150A1 (de) * | 1985-11-13 | 1987-05-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4868164A (en) * | 1986-12-19 | 1989-09-19 | Norwich Eaton Pharmaceuticals, Inc. | Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
-
1986
- 1986-12-19 US US06/945,069 patent/US4868164A/en not_active Expired - Lifetime
-
1987
- 1987-11-30 IL IL8466087A patent/IL84660A/en not_active IP Right Cessation
- 1987-12-10 MY MYPI87003173A patent/MY102266A/en unknown
- 1987-12-16 EP EP87202533A patent/EP0273514B1/en not_active Expired - Lifetime
- 1987-12-16 DE DE8787202533T patent/DE3766695D1/de not_active Expired - Fee Related
- 1987-12-16 AT AT87202533T patent/ATE59046T1/de not_active IP Right Cessation
- 1987-12-17 CA CA000554628A patent/CA1321793C/en not_active Expired - Fee Related
- 1987-12-18 DK DK670387A patent/DK171068B1/da not_active IP Right Cessation
- 1987-12-18 ZA ZA879502A patent/ZA879502B/xx unknown
- 1987-12-18 NZ NZ222985A patent/NZ222985A/xx unknown
- 1987-12-18 PH PH36260A patent/PH25583A/en unknown
- 1987-12-18 NO NO875305A patent/NO174625C/no not_active IP Right Cessation
- 1987-12-18 IE IE873456A patent/IE873456L/xx not_active IP Right Cessation
- 1987-12-18 FI FI875595A patent/FI87652C/fi not_active IP Right Cessation
- 1987-12-18 AU AU82809/87A patent/AU615886B2/en not_active Ceased
- 1987-12-19 JP JP62322651A patent/JP2573973B2/ja not_active Expired - Fee Related
- 1987-12-19 KR KR1019870014561A patent/KR950009196B1/ko not_active IP Right Cessation
-
1989
- 1989-09-14 US US07/407,848 patent/US5137880A/en not_active Expired - Lifetime
-
1992
- 1992-06-17 US US07/899,794 patent/US5393746A/en not_active Expired - Fee Related
- 1992-06-29 NO NO922565A patent/NO176144C/no not_active IP Right Cessation
-
1993
- 1993-08-05 HK HK793/93A patent/HK79393A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK79393A (en) | 1993-08-13 |
FI875595A0 (fi) | 1987-12-18 |
IL84660A (en) | 1994-10-21 |
DK171068B1 (da) | 1996-05-20 |
ATE59046T1 (de) | 1990-12-15 |
NZ222985A (en) | 1990-09-26 |
FI875595A (fi) | 1988-06-20 |
IE873456L (en) | 1988-06-19 |
PH25583A (en) | 1991-08-08 |
FI87652C (fi) | 1993-02-10 |
US5137880A (en) | 1992-08-11 |
FI87652B (fi) | 1992-10-30 |
NO922565D0 (no) | 1992-06-29 |
NO176144B (no) | 1994-10-31 |
DK670387A (da) | 1988-06-20 |
DE3766695D1 (de) | 1991-01-24 |
NO176144C (no) | 1995-02-08 |
DK670387D0 (da) | 1987-12-18 |
EP0273514A1 (en) | 1988-07-06 |
JP2573973B2 (ja) | 1997-01-22 |
US5393746A (en) | 1995-02-28 |
CA1321793C (en) | 1993-08-31 |
NO922565L (no) | 1988-06-20 |
US4868164A (en) | 1989-09-19 |
NO875305D0 (no) | 1987-12-18 |
ZA879502B (en) | 1988-06-16 |
AU8280987A (en) | 1988-06-23 |
IL84660A0 (en) | 1988-04-29 |
MY102266A (en) | 1992-05-15 |
NO174625C (no) | 1994-06-08 |
KR950009196B1 (ko) | 1995-08-16 |
AU615886B2 (en) | 1991-10-17 |
EP0273514B1 (en) | 1990-12-12 |
NO174625B (no) | 1994-02-28 |
JPS63239290A (ja) | 1988-10-05 |
NO875305L (no) | 1988-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880007473A (ko) | 신규의 비사이클릭디포스포네이트 화합물 | |
OA09482A (fr) | "Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent". | |
ES543805A0 (es) | Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo dialquilaminoalcoxi sustituido y de sus sa-les de adicion acidas y amonicas cuaternarias | |
ES547604A0 (es) | Un procedimiento para preparar derivados de 2-piridin-tiol | |
ES528459A0 (es) | Procedimiento de preparacion de nuevos derivados 1-hidroxipropil resorcinos provistos de un grupo fenilo sustituidos. | |
ES528458A0 (es) | Procedimiento de preparacion de nuevos derivados 4-hidroxi- -etil-benzoles | |
ATE26271T1 (de) | Benzhydrylpiperazine-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
KR950701927A (ko) | 비정상 칼슘 및 인산염 대사를 치료하기 위한 4급 질소 함유 포스포네이트 화합물(quaternary nitrogen-containing phosphonate compounds, for treating abnormal calcium and phosphate metabolism) | |
ATE4541T1 (de) | Alkyl- und cycloalkylsubstituierte 2-(2-(2hydroxy-3-tert.-butylamino-propoxy)-5-acylamino phenyl)-1,3,4-oxadiazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen. | |
KR920012065A (ko) | 치환 디벤즈-옥사-티오시논, -12-옥시드 및 -12, 12- 디옥시드, 이들의 제조 방법 및 의약으로서의 이들의 용도 | |
ES485333A1 (es) | Procedimiento para preparar derivados 5,6,7,8-tetrahidro-4 (3h)-quinazolinonicos y sus sales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G160 | Decision to publish patent application | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20000707 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |